Carole Mitnick, Sc.D. is Professor of Global Health & Social Medicine at Harvard Medical School and Associate Epidemiologist in the Division of Global Health Equity at Brigham & Women’s Hospital. Trained in international health epidemiology and ecology at Harvard TH Chan School of Public Health, she has more than 20 years of experience in programmatic support, research, policy, and advocacy related to increased access to high-quality, appropriate treatment for TB, especially for drug-resistant TB. Dr. Mitnick’s contributions to the field have come through observational and experimental research, all in close collaboration with Partners In Health. She is currently the co-PI of two multi-country, phase III, randomized, controlled, clinical trials of all-oral, shortened, novel regimens for rifampin-resistant TB. She has also worked NTPs in multiple countries, notably Peru, Haiti, Kazakhstan, DR Congo, and Lesotho, supporting scale up of MDR-TB treatment. She is a founding member of RESIST-TB.